Julie Vose, MD

Julie Vose, MD

Term to Begin June 2015

Oncologist Julie Vose, MD, has been elected president of the American Society of Clinical Oncology (ASCO) for a one-year term beginning in June 2015. Dr. Vose will take office as president-elect during the ASCO annual meeting in Chicago in June 2014.

“ASCO is a very diverse and multifaceted organization with so much to offer its membership,” Dr. Vose says. “I am excited to serve the ASCO membership as president and to make a difference for oncology professionals and our patients.”

Dr. Vose cited the recent enhancements in the society’s educational offerings, quality improvement and broadened advocacy as areas where her experience and training can add to the current ASCO activities, including CancerLinQ(TM), ASCO’s groundbreaking health information technology initiative to achieve higher quality, higher value cancer care with better outcomes for patients.

Ken Cowan, MD, PhD, director of the Fred & Pamela Buffett Cancer Center, calls the election a great honor for Dr. Vose and UNMC. “She is an internationally recognized leader in clinical trials in lymphoma,” he says. “As the leader of the largest organization of clinical oncologists, she will be able to have a major impact on the future directions of clinical research and clinical care in cancer.”

Dr. Vose’s election and involvement in ASCO and other national oncology organizations are a credit to UNMC as well as Dr. Vose, says James Armitage, MD, Joe Shapiro Professor of Internal Medicine in the Division of Oncology/Hematology.

“I’m incredibly proud of Julie and what she’s accomplished,” Dr. Armitage says. “This is the most visible and one of the most important oncology positions in the world. It reflects her excellence in clinical medicine and research.”

Dr. Vose is the associate director of clinical research and co-chair of the lymphoma program at the Fred & Pamela Buffett Cancer Center. Since joining ASCO in 1991, she has served on the board of directors, as chair of the Cancer Education Committee and is the current chair-elect of the Integrated Media and Technology Committee, among other activities.

ASCO’s board of directors is comprised of oncology leaders who are elected to positions reflecting various specialties within the oncology field.